Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fever After Tick Bite Study (FATB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03932448
Recruitment Status : Recruiting
First Posted : April 30, 2019
Last Update Posted : May 16, 2019
Sponsor:
Collaborators:
Sahlgrenska University Hospital, Sweden
Vastra Gotaland Region
Information provided by (Responsible Party):
Göteborg University

Brief Summary:

The proposed study is a collaboration between Microbiology, SU/Sahlgrenska and the Infectious Diseases clinic at SU/Östra as well as several Infectious Diseases clinics throughout Sweden aiming at improving microbiological diagnostic assays regarding the early identification of tick-borne microorganisms (including as of yet unidentified pathogens) capable of causing human disease using modern diagnostic tools.

At the initial study visit (day 0) plasma, serum, urine, saliva, and PBMCs (and tick, if available) will be collected from patients developing fever within two weeks after a tick bite. Additional follow-up samples will be obtained after 9 and 30 days as well as after 6 months. The initial samples will be analyzed using (a) directed multiplex PCR analysis for Tick-Borne Encephalitis (TBE), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella, Tularemia, and Babesiosis in plasma, whole blood and urine, (b) conventional IgM and IgG serology for TBE, (c) "Next Generation Sequencing" (NGS) for the detection of bacterial 16s rRNA as well as unknown viruses, (d) potential biomarkers, and (e) host genetic factors. Among patients where initial sampling indicates the presence of a potential pathogen or in patients developing neurological symptoms, a lumbar puncture will be performed and CSF will be further analyzed. Samples will also be evaluated regarding potential microbiological factors predisposing for severity of infection.

The primary objective of the study is to improve diagnostic tools in the initial early phase of infections caused by tick-borne pathogens, especially TBE prior to the affliction of the central nervous system, and to attempt to identify which factors impact the course of infection as it is believed that approximately 75% of infected individuals resolve their infection in this first phase whereas others develop meningoencephalitis with significant subsequent neurological sequelae. Secondary objectives of the study include investigating for the presence of and treating other tick-borne pathogens, setting the stage for coming clinical trials evaluating novel anti-viral therapies for TBE.


Condition or disease Intervention/treatment
Tick-Bite; Fever Tick Fever Tick-Borne Diseases Encephalitis, Tick-Borne Tick Bites Other: The proposed study is not interventional.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 310 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Fever After Tick Bite (FATB) Study; Determining the Etiology of Tick-Borne Human Infections in Northern Europe
Actual Study Start Date : May 15, 2019
Estimated Primary Completion Date : December 20, 2022
Estimated Study Completion Date : February 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fever Tick Bites


Intervention Details:
  • Other: The proposed study is not interventional.
    The proposed study is not interventional. However, if a treatable microorganism is detected, e.g. Borrelia or Anaplasma, suitable therapy, e.g. doxycycline, will be in initiated if appropriate.


Primary Outcome Measures :
  1. Etiology of fever (≥38°C) developing within 2 weeks after a tick bite. [ Time Frame: Up to two weeks after the tick bite. ]
    Number of participants with detectable Tick-Borne Encephalitis Virus (TBEV), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella burnetii, Tularemia, and/or Babesia infections.

  2. Proportion of subjects developing neurological symptoms after a tick bite. [ Time Frame: Up to six months after the tick bite. ]
    The proportion of subjects developing neurological symptoms in each of the following etiological categories: Tick-Borne Encephalitis Virus (TBEV), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella burnetii, Tularemia, and/or Babesia.

  3. Proportion of subjects developing other serious, non-neurological symptoms or disease after a tick bite. [ Time Frame: Up to six months after the tick bite. ]
    The proportion of subjects developing other serious, non-neurological symptoms or disease in each of the following etiological categories: Tick-Borne Encephalitis Virus (TBEV), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella burnetii, Tularemia, and/or Babesia.


Secondary Outcome Measures :
  1. Impact of body mass index (BMI) of subjects on the risk of development of neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of body mass index (weight and height will be combined to report BMI in kg/m2) of subjects developing vs. not developing neurological symptoms.

  2. Impact of waist circumference of subjects on the risk of development of neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of waist circumference (measured in cm) of subjects developing vs. not developing neurological symptoms.

  3. Impact of gender of subjects on the risk of development of neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of gender (male vs. female) of subjects developing vs. not developing neurological symptoms.

  4. Impact of age of subjects on the risk of development of neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of age (measured in years) of subjects developing vs. not developing neurological symptoms.

  5. Impact of body mass index of subjects developing other serious, non-neurological symptoms or disease. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of body mass index (weight and height will be combined to report BMI in kg/m2) of subjects developing vs. not developing other serious, non-neurological symptoms or disease.

  6. Impact of waist circumference of subjects developing other serious, non-neurological symptoms or disease. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of waist circumference (measured in cm) of subjects developing vs. not developing other serious, non-neurological symptoms or disease.

  7. Impact of gender of subjects developing other serious, non-neurological symptoms or disease. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of gender (male vs. female) of subjects developing vs. not developing other serious, non-neurological symptoms or disease.

  8. Impact of age of subjects developing other serious, non-neurological symptoms or disease. [ Time Frame: Up to six months after the tick bite. ]
    Evaluation of age (measured in years) of subjects developing vs. not developing other serious, non-neurological symptoms or disease.

  9. Prospective evaluation of the utility of Next Generation Sequencing (NGS) for the detection of unknown viruses and of bacterial 16s rRNA vs. directed Multiplex PCR [ Time Frame: Up to 30 days after the tick bite. ]
    Number of participants with Tick-Borne Encephalitis Virus (TBEV), Borrelia, Anaplasma, Neoerlichia, Rickettsia, Coxiella burnetii, Tularemia, and/or Babesia infections as detected using Next Generation Sequencing (NGS) in comparison to Multiplex Polymerase Chain Reaction (Multiplex PCR).

  10. Prospective evaluation of the specificity and sensitivity of TBEV-RNA and TBE IgM serology in the early phase of infection, i.e. up to 30 days after the tick bite. [ Time Frame: Up to 30 days after the tick bite. ]
    Comparison of the number of subjects correctly identified as being infected with TBEV by means of analysis of TBEV-RNA vs. TBE IgM serology in the early phase of infection, i.e. up to 30 days after the tick bite.

  11. Prospective evaluation of the specificity and sensitivity of TBEV-RNA in urine vs. plasma/whole blood in the early phase of TBE infection, i.e. up to 30 days after the tick bite. [ Time Frame: Up to 30 days after the tick bite. ]
    Comparison of the number of subjects correctly identified as being infected with TBEV by means of analysis of TBEV-RNA in urine vs. plasma/whole blood in the early phase of TBE infection, i.e. up to 30 days after the tick bite.

  12. Prospective evaluation of the specificity and sensitivity of PCR for Borrelia DNA in plasma/serum as well as Borrelia IgM serology in the early phase of infection, i.e. up to 30 days after the tick bite. [ Time Frame: Up to 30 days after the tick bite. ]
    Comparison the number of subjects correctly identified as being infected with Borrelia by means of analysis of PCR for Borrelia DNA in plasma/serum as well as Borrelia IgM and IgG serology in the early phase of infection, i.e. up to 30 days after the tick bite.

  13. Prospective evaluation of the specificity and sensitivity of early evaluation of plasma concentrations of the neurological markers NFL in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of the neurological marker NFL will be evaluated among subjects developing vs. not developing neurological symptoms.

  14. Prospective evaluation of the specificity and sensitivity of early evaluation of plasma concentrations of the neurological marker T-tau in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of the neurological marker T-tau will be evaluated among subjects developing vs. not developing neurological symptoms.

  15. Prospective evaluation of the specificity and sensitivity of early evaluation of plasma concentrations of the neurological marker GFAp in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of neurological marker GFAp will be evaluated among subjects developing vs. not developing neurological symptoms.

  16. Prospective evaluation of the specificity and sensitivity of early evaluation of plasma concentrations of IP-10 (aka CXCL10) in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of IP-10 (aka CXCL10) will be evaluated among subjects developing vs. not developing neurological symptoms.

  17. Prospective evaluation of the specificity and sensitivity of early evaluation of 25-hydroxy vitamin D (25(OH)D) concentrations in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of plasma concentrations of 25-hydroxy vitamin D (25(OH)D) will be evaluated among subjects developing vs. not developing neurological symptoms.

  18. Prospective evaluation of peripheral blood mononuclear cells (PBMCs) analyzed by FACS, in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Comparison of the proportion of CD56 negative NK, CD4+ CD38+, CD8+ CD38+, CD8+CD16+, Foxp3+, and pDC (CD303+) cells analyzed by FACS will be evaluated among subjects developing vs. not developing neurological symptoms.

  19. Prospective evaluation of the impact of host genetic polymorphisms in the IFNL4 gene in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Proportion of subjects with genetic polymorphisms in the IFNL4 gene evaluated among subjects developing vs. not developing neurological symptoms.

  20. Prospective evaluation of the impact of host genetic polymorphisms in the ITPA gene in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    Proportion of subjects with genetic polymorphisms in the ITPA gene evaluated among subjects developing vs. not developing neurological symptoms.

  21. Prospective evaluation of the impact of prior vaccination against TBE on frequency and outcome of TBEV infection. [ Time Frame: From time of prior vaccination until six months after the tick bite. ]
    Comparison of subjects with vs. without prior vaccination against TBE on frequency and outcome of TBEV infection.

  22. Prospective evaluation of the impact of prior vaccination against Yellow Fever on frequency and outcome of TBEV infection. [ Time Frame: From time of prior vaccination until six months after the tick bite. ]
    Comparison of subjects with vs. without prior vaccination against Yellow Fever on frequency and outcome of TBEV infection.

  23. Prospective evaluation of the impact of prior vaccination against Japanese Encephalitis on frequency and outcome of TBEV infection. [ Time Frame: From time of prior vaccination until six months after the tick bite. ]
    Comparison of subjects with vs. without prior vaccination against Japanese Encephalitis on frequency and outcome of TBEV infection.

  24. Prospective evaluation of the association between presence or absence of immunosuppression in relation to the likelihood of developing neurological symptoms. [ Time Frame: Up to six months after the tick bite. ]
    The proportion of subjects with vs. without immunosuppression will be evaluated among subjects developing vs. not developing neurological symptoms.


Biospecimen Retention:   Samples With DNA
Plasma, serum, urine, saliva, and PBMCs will be sampled and stored.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Men and women ≥18 years old with documented or a medical history of fever (≥38°C) within 2 weeks after a tick bite.
Criteria

Inclusion Criteria:

  • Written informed consent
  • Male and female patients ≥18 years of age
  • Medical history of tick bite within past 2 weeks
  • Documented or medical history of fever (≥38°C) within past 2 weeks

Exclusion Criteria:

  • Inability or unwillingness to provide informed consent or abide by the requirements of the study
  • Presence of urinary tract symptoms
  • Presence of non-tick related, infectious agent causing fever, e.g. a respiratory virus
  • Presence of other medical, non-infectious cause of fever

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03932448


Contacts
Layout table for location contacts
Contact: Martin Lagging, MD, PhD +46-(0)31-342 47 31 martin.lagging@medfak.gu.se
Contact: Marie Studahl, MD, PhD +46- (0)31-343 57 48 marie.studahl@infect.gu.se

Locations
Layout table for location information
Sweden
Dept. of Infectious Diseases Recruiting
Gothenburg, Sweden
Contact: Martin Lagging, MD PhD    +46-(0)31-342 47 31    martin.lagging@medfak.gu.se   
Contact: Marie Studahl, MD PhD    +46-31-343 57 48‬    marie.studahl@infect.gu.se   
Sponsors and Collaborators
Göteborg University
Sahlgrenska University Hospital, Sweden
Vastra Gotaland Region
Investigators
Layout table for investigator information
Principal Investigator: Martin Lagging, MD, PhD Göteborg University

Layout table for additonal information
Responsible Party: Göteborg University
ClinicalTrials.gov Identifier: NCT03932448     History of Changes
Other Study ID Numbers: FATB Study Group
First Posted: April 30, 2019    Key Record Dates
Last Update Posted: May 16, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tick-Borne Diseases
Encephalitis, Tick-Borne
Encephalitis
Fever
Bites and Stings
Tick Bites
Body Temperature Changes
Signs and Symptoms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Poisoning
Chemically-Induced Disorders
Wounds and Injuries
Encephalitis, Arbovirus
Arbovirus Infections
Virus Diseases
Encephalitis, Viral
Central Nervous System Viral Diseases
RNA Virus Infections
Flavivirus Infections
Flaviviridae Infections
Infectious Encephalitis
Central Nervous System Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Protozoan Infections
Parasitic Diseases